Recurrent rearrangements of 11q14–22 in mucoepidermoid carcinoma

doi:10.1016/0165-4608(94)90001-9

Cancer Genetics and Cytogenetics

Volume 74, Issue 2, June 1994, Pages 77-83

https://doi.org/10.1016/0165-4608(94)90001-9 Get rights and content

Abstract

We describe the cytogenetic findings in five mucoepidermoid carcinomas (MEC) of the major and minor salivary glands. Three of the five tumors analyzed showed an apparently identical t(11;19)(q14–21;p12). In one case, the t(11;19) was the only common clonal abnormality, while in the other two cases the translocation was found together with +16, +20, and inv(1)(p32–33q42), t(6;15)(p12;q25), respectively. The latter case also showed an interstitial short arm deletion of the der(11) chromosome. Of the two remaining cases, one had a del(3)(p13p23) as the sole karyotypic abnormality, while the other had a hyperdiploid stemline characterized by the following numerical deviations: +2, +5, +6, +7, +8, +17, +18, and +19. These findings, together with previously published data from seven MEC, indicate that at least two different, partially overlapping cytogenetic subgroups exist: 1) cases with structural rearrangements of 11q14–22; the finding of three tumors with an apparently identical t(11;19)(q14–21;p12) demonstrates that this is a non-random, and possibly primary abnormality in MEC, and 2) single or multiple trisomies, either observed as the sole anomalies or in combination with structural rearrangements.

References (17)

J Sandros et al.
Specificity of 6q− markers and other recurrent deviations in human malignant salivary gland tumors
Anticancer Res
(1988)
A Nordkvist et al.
Multiple unrelated chromosome abnormalities in a metastatic mucoepidermoid carcinoma of the parotid gland
Cancer Genet Cytogenet
(1992)
G Stenman et al.
Loss of the Y chromosome in a cultured human salivary gland adenocarcinoma
J Oral Pathol
(1983)
J Mark et al.
A human adenolymphoma showing the chromosomal aberrations del(7)(p12p14–15) and t(11;19)(q21;p12–13)
Anticancer Res
(1989)
G Stenman et al.
Partial 6q deletion in a human salivary gland adenocarcinoma
Cancer Genet Cytogenet
(1989)
J Sandros et al.
Cytogenetic and molecular observations in human and experimental salivary gland tumors
Cancer Genet Cytogenet
(1990)
J Mark et al.
Complex chromosomal changes in a primary squamous cell carcinoma of the parotid gland
Anticancer Res
(1993)
G Seifert et al.
Diseases of the Salivary Glands. Pathology-Diagnosis-Treatment-Facial nerve surgery
G Seifert et al.
Diseases of the Salivary Glands. Pathology-Diagnosis-Treatment-Facial nerve surgery

There are more references available in the full text version of this article.

Cited by (116)

MAML2 gene rearrangement occurs in all Warthin-like mucoepidermoid carcinoma: A reappraisal in a series of 29 cases
2024, Heliyon
Warthin-like Mucoepidermoid carcinoma (MEC) is a new and rare morphological variant of MEC, with only a few case reports in the literature. The clinicopathological, molecular features and bio-behaviors of Warthin-like MEC has not been studied extensively. We reappraisal all Warthin-like MEC patients diagnosed and treated at our hospital.
Patient characteristics including clinicopathological features, genetic aberrations, treatment, and prognostic information were assessed and evaluated.
Twenty-nine Warthin-like MEC patients were identified, 19 patients were female (65.5 %), and 10 were male (34.5 %). The patients’ age varied widely from 8 to 68 years (mean 42.3 years). Genetic aberrations of MAML2 rearrangement were detected in all Warthin-like MEC patients, which suggesting this genetic event is the unique feature of Warthin-like MEC. Twenty-five patients (86.2 %) were assessed as having a low-stage disease (I/II), and four (13.8 %) as having high-clinical stage disease (III/IV). More than half of the patients (16/29) underwent only partial sialoadenectomy; 2 patients underwent extended sialoadenectomy, and 11 patients underwent extended sialoadenectomy with cervical lymph node dissection. After a median follow-up time of 73 months (5–128 months), Twenty-eight patients were alive without recurrence at the end of the follow-up period, one patient died 1 year after surgery due to lung metastasis.
Our data suggested that most Warthin-like MEC exhibited mild clinicopathological course and less aggressive bio-behavior, and an aggressive bio-behavior seemed to be very rare. In addition, in the salivary gland, MAML2 rearrangement seems to be a unique molecular feature of salivary Warthin-like MEC.
HER2-targeted therapies for salivary gland cancers
2024, Oral Oncology
Salivary gland cancers (SGCs) are a heterogeneous group of rare tumors including various histological subtypes with different molecular profiling. Human epidermal growth factor receptor 2 (HER2) is one of the most intriguing and studied molecular alterations with prognostic and predictive roles. Indeed, HER2 overexpression is commonly correlated with aggressive histological subtypes and poorer prognosis. However, HER2 may represent the target of personalized treatment.
We performed a literature review of use of anti-HER2 targeted agents for treatment of recurrent or metastatic SGCs. The efficacy and safety of anti-HER2 were firstly evaluated in patients affected with other solid tumors, mostly breast and gastric cancers. For SGCs the literature is mainly comprised of case reports or case series and small clinical trials. The most common used drug is trastuzumab in combination with chemotherapy (i.e. taxanes, capecitabine, carboplatin, eribulin) or with another anti-HER2 targeted agent (i.e. pertuzumab). The use of anti-HER2 therapies induces improvement in clinical responses, which are mostly durable. Besides, new anti-HER2 drugs such as antibody-drug conjugates (ADC) (i.e. trastuzumab emtansine, trastuzumab deruxtecan) have been introduced in this setting inducing further therapeutic advances.
Anti-HER2 treatment strategy is emerging as potentially effective in selected HER2 overexpressing SGCs. However, prospective and multicentric clinical trials are needed to evaluate the efficacy of these therapeutic regimens within larger cohorts and to assess the most appropriate treatment sequence strategy.
Genetic and Immunohistochemical Profiling of Mammary Hidradenoma and Comparison to Mucoepidermoid Carcinoma
2023, Modern Pathology
Mucoepidermoid carcinoma (MEC) is exceedingly rare in the breast, with <45 cases reported in the literature. Although estrogen receptor/progesterone receptor/human epidermal growth factor 2 triple-negative, MEC is characterized as a special subtype of breast carcinoma with significantly better prognosis than conventional basal-type tumors. Cutaneous hidradenoma (HA) is considered a benign adnexal neoplasm showing histomorphologic overlap with MEC. Rare cases of HA have also been reported in the breast, but these are relatively uncharacterized. In this study, we examined the clinicopathologic, immunohistochemical (IHC), and genetic features of 8 breast HAs, in comparison to 3 mammary MECs. All cases were positive for MAML2 break-apart fluorescence in situ hybridization. Eight cases demonstrated a CRTC1::MAML2 fusion, and one MEC harbored a CRTC3::MAML2 fusion; the latter is a novel finding in the breast. Mutational burden was very low, with only one HA exhibiting a MAP3K1 pathogenic alteration. By IHC, both MEC and HA demonstrated cell type–dependent expression of high- and low-molecular-weight keratins and p63, as well as negative to low-positive estrogen receptor and androgen receptor. Smooth muscle myosin and calponin highlighted an in situ component in the 3 cases of MEC; expression of these myoepithelial markers was negative in HAs. Additional distinguishing characteristics included the growth pattern and tumor architecture, the presence of glandular/luminal cells in HA, and overall higher IHC expression of SOX10, S100 protein, MUC4, and mammaglobin in MEC. Morphologic findings were also compared to a series of 27 cutaneous nonmammary HAs. Mucinous and glandular/luminal cells were identified in significantly more mammary HAs than nonmammary lesions. The findings provide insight into the pathogenesis of MAML2-rearranged neoplasms of the breast, underscore the overlapping genetic features of MEC and HA, and highlight similarities to their extramammary counterparts.
Primary Mucoepidermoid Carcinoma of the Lacrimal Apparatus
2022, American Journal of Ophthalmology
In this study, we evaluated the clinicopathologic and molecular characteristics of lacrimal apparatus mucoepidermoid carcinoma (MEC) to define its typical diagnostic features.
Retrospective observational case series.
Institutional pathology records between 2011 and 2021 were searched for all cases of lacrimal apparatus MEC.
A total of 2 male and 6 female patients ranging in age from 18 to 83 years (median 56, mean 54) were included. Six lacrimal apparatus MECs were found in the lacrimal gland, and 2 cases occurred in the lacrimal sac and nasolacrimal duct. Histologically, there were 6 cases of conventional MEC, 1 clear-cell variant of MEC, and 1 oncocytic variant of MEC for a total of 8 cases. There were 3 low-grade cases and 5 high-grade cases. All 8 cases were evaluated via immunohistochemistry, and the results were positive (scores 1-4) for pankeratin, 34betaE12, p63, p40, CK7, CK8, and CK19, with a relatively higher expression of p63 observed in high-grade MEC. The presence of human papillomavirus (HPV) type 6 DNA was found in 4 patients. MAML2 fluorescence in situ hybridization was positive for MAML2 rearrangement in 3 lacrimal gland tumors (2 low-grade and 1 high-grade). Six tumors were managed with radical resection, and 2 patients underwent orbital exenteration. Postoperative radiation therapy was delivered to 6 patients, and chemotherapy was administered to 1 patient.
MECs of the lacrimal apparatus are rare tumors, and the rate of MAML2 translocations is lower than that in salivary MECs. Lacrimal gland and lacrimal sac MECs may not be of the same subtypes intrinsically because of the difference in MAML2 translocation, anatomy, and clinical course. The etiologic function of HPV type 6 infection should be explored in lacrimal apparatus MECs. Radical surgery is the treatment of choice. The description of these unique findings may assist in the definitive diagnosis of and improve our understanding of lacrimal apparatus MEC.
The significance of mucinous metaplasia in Warthin tumor: a frequent occurrence and potential pitfall
2020, Human Pathology
Mucinous metaplasia in Warthin tumor (WT) is a recognized phenomenon. Nevertheless, its presence can create a diagnostic challenge in the distinction from the newly proposed variant of mucoepidermoid carcinoma (MEC), Warthin-like MEC. In this study, we evaluated the significance and diagnostic relevance of mucinous metaplasia in WTs. A total of 30 WTs diagnosed based on resection specimens formed the basis of this retrospective study. Mucicarmine staining was performed to identify mucinous metaplasia, and fluorescence in situ hybridization (FISH) analysis was used to detect MAML2 gene rearrangement. After review, one MAML2 rearranged case was reclassified as Warthin-like MEC as the classic bilayered epithelium in WT was not identified. The diagnosis of WT was confirmed in the remaining 29 cases. Mucinous metaplasia was encountered in 24 WTs (83%), with 14% (4/29) having an abundant amount. We found that mucinous metaplasia correlated with tumor size (p < 0.05). Age and sex distribution were similar in WT cases with or without mucinous metaplasia. In addition, neither the presence of squamous metaplasia nor the time interval between fine-needle aspiration and surgery was related to mucinous metaplasia (p > 0.05). The MAML2 FISH analyses performed in 18 WTs with variable amounts of mucinous metaplasia were negative for rearrangement. In conclusion, mucinous metaplasia is fairly common in WTs and shows a significant correlation with tumor size. Therefore, caution should be taken to avoid overinterpretation of WT with mucinous metaplasia as MEC in cases showing the classic bilayered oncocytic lining epithelium.
Mucoepidermoid carcinoma of the pancreas A case report and literature review
2024, Medicine (United States)

View all citing articles on Scopus

^☆: This study was supported by grants from the Assar Gabrielsson Research Foundation, the Swedish Society for Medical Research, the Inga Britt och Arne Lundbergs Research Foundation, and the Swedish Cancer Society.

View full text

Lead articleRecurrent rearrangements of 11q14–22 in mucoepidermoid carcinoma☆

Abstract

Anticancer Res

Cancer Genet Cytogenet

J Oral Pathol

Anticancer Res

Cancer Genet Cytogenet

Cancer Genet Cytogenet

Anticancer Res

Diseases of the Salivary Glands. Pathology-Diagnosis-Treatment-Facial nerve surgery

Diseases of the Salivary Glands. Pathology-Diagnosis-Treatment-Facial nerve surgery

Lead article
Recurrent rearrangements of 11q14–22 in mucoepidermoid carcinoma☆